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203 Low dose azithromycin may slow the decline of respiratory
function in cystic ﬁbrosis
G. Pisi1, D. Tripodi1. 1University Hospital of Parma, Pediatric Clinic − UO Cystic
Fibrosis, Parma, Italy
Background: The positive effect of azithromycin (AZM) on lung function in Cystic
Fibrosis (CF) patients have been showed by many clinical trials, but studies were
less long than 1 year.
Aim: To evaluate the effect of a long course of low dose AZM on lung function
in CF patients.
Subjects and Methods: 43 patients (26 F) with chronic infection by Pseudomonas
aeruginosa (PA), age ranged between 6 and 39 years (mean ±SD: 17.8±7.4 years)
had a AZM (250mg/day) 3-years treatment. In all patients FVC, FEV1, FEF 25−75,
expressed as percentage of predicted, and SpO2 (%), were measured at 3 month
intervals and were compared with the corresponding values recorded at 3 month
intervals during 3 years before starting AZM treatment. Linear regression analysis
was used and a p value <0.05 was considered as signiﬁcant.
Results: The change in lung function and oxygen saturation observed during the
3 years before starting AZM treatment was signiﬁcantly different from that during
the 3 years, when patients were treated (table).
FVC FEV1 FEF25/75 SpO2
Before AZM −2.7±1.1* −3.6±1.2* −5.7±1.7* −0.2±0.1*
During AZM 0.5±1.1* 0.2±1.2* −0.1±1.7* 0.2±0.1*
*p< 0.05.
Conclusions: Our results show that in patients with CF low dose AZM treatment
can slow the decline in pulmonary function, in spite of the increase of age and
worsening in pulmonary disease.
204 Effect of combination of inhaled corticosteroids and long acting
beta two agonists (LABA) on airways resistance (Rint) among
preschoolers with cystic ﬁbrosis
E. Hatziagorou1, V. Avramidou1, S. Botskariova1, F. Kirvasillis1, J. Tsanakas1.
1Hippokration Hospital, Aristotle University of Thessaloniki, 3rd Paediatric Dept,
Thessaloniki, Greece
Background: In cystic ﬁbrosis (CF) lung function testing is a tool for monitoring
progression of lung disease. Bronchodilators are used in CF as a therapeutic tool
to facilitate airway clearance and to provide protection against bronchoconstrictors
of various drugs.
Aim: The objectives of this study were: (a) To compare airways resistance measured
by interrupter technique (Rint) among 28 preschool children with CF and 27 healthy
controls. (b) To assess the relationship of Rint with atopy and (c) To assess the effect
of inhaled corticosteroids plus LABA on Rint among preschoolers with CF.
Method: 28 preschoolers with CF (mean age 3.55± 1.56 years) and recurrent cough
and wheeze and 27 healthy control children were studied. 13/28 children with CF
were on prophylaxis with inhaled corticosteroids plus LABA for six months. Rint
and total serum IgE were measured.
Results: As compared with control children, children with CF had signiﬁcantly
higher Rint, (1.183±0.39 vs 0.79 ± 0.20 kPa L−1 second, p< 0.001). Rint was
not correlated with history of atopy (p = 0.137), or total IgE (p = 0.372, R = 0.259)
among children with CF. Rint z-scores were signiﬁcantly lower in children who
were on inhaled corticosteroids plus LABA, compared to those on no anti-asthmatic
prophylaxis (p = 0.025).
Conclusions: Preschoolers with CF have signiﬁcantly higher Rint than healthy
children. Children with CF and with a history of respiratory symptoms may beneﬁt
from inhaled corticosteroids plus LABA.
205 Predictors of time to next exacerbation in adults with
cystic ﬁbrosis
R.L. Dentice1,2, M.R. Elkins1,2, P.T. Bye1,2. 1Royal Prince Alfred Hospital,
Respiratory Medicine, Sydney, Australia; 2University of Sydney, Sydney Medical
School, Sydney, Australia
Background: Being able to predict the time to next hospital admission for respi-
ratory exacerbation could be useful in guiding the provision of outpatient services
and in designing clinical trials with time to next exacerbation as an outcome. This
study aimed to examine variables that can be measured at discharge from hospital
after a respiratory exacerbation to determine whether they could predict the time
to the next hospital admission for a respiratory exacerbation.
Methods: Data were collected prospectively from 110 adults with cystic ﬁbrosis
who were admitted to hospital consecutively for a respiratory exacerbation. The
variables initially considered as potential predictors of time to next exacerbation
included: best lung function in the prior 6 months, reduction in lung function
between best and admission, lung function and symptom severity at admission
and at discharge, length of admission, and gender. Wherever there was substantial
collinearity (r>0.80) between multiple variables, one of the correlated variables was
chosen for use in a multiple regression analysis.
Results: Five variables without collinearity were analysed: FEV1 at admission,
reduction in FEV1 at admission, symptom severity at admission, best FVC in the
prior 6 months, and length of stay. Only two variables accounted for >10% of the
variability in time to next exacerbation: FEV1 at admission (18%) and best FVC
(11%). A multiple regression model with these predictors only accounted for 21%
of the variability.
Conclusion: The variables we examined (individually or combined in a model) did
not provide clinically useful prediction of the time to next exacerbation in adults
with cystic ﬁbrosis.
206 Eosinopenia and severity of pulmonary exacerbations in adult
cystic ﬁbrosis patients
K. Williams1, K. Powell1, P. Whitaker1, R. Naseer1, S. Deshmukh2, S. Conway1,
D. Peckham1. 1St James’s University Hospital, Regional Adult Cystic Fibrosis
Unit, Leeds, United Kingdom; 2St James’s University Hospital, Leeds, United
Kingdom
Objectives: Previous studies have shown eosinopenia to be associated with in-
creased mortality and severity in COPD exacerbations and to be a reliable marker
of sepsis in critically ill patients. This study aims to assess whether there is an
association between eosinopenia and severity of pulmonary exacerbations of CF.
Methods: A retrospective analysis of all patients receiving i.v. antibiotics for
pulmonary exacerbations between 01/12/2008 and 01/12/2009 was undertaken. Data
from patients with a low eosinophil count (<0.04 10*9/L) were compared to the
remainder. Data from patients who were pregnant, post transplant, on continuous
i.v. antibiotic therapy or without a full blood count were excluded.
Conclusions: Over a 12 month period there were 411 exacerbations in 185 patients.
Eosinopenia was found in 19 exacerbations (4.6 % prevalence). There were no
signiﬁcant differences between the two groups in terms of age, sex, FEV1 at start,
total white cell count, Pseudomonas status, diabetes or use of LTOT/NIV. Patients
with eosinopenia were no more likely to require in-patient treatment, although there
was a trend towards this. No patients with eosinopenia had a positive throat swab
for viral PCR. Exacerbations with eosinopaenia had a higher pre-treatment CRP
and a longer duration of treatment than controls (Table 1).















Eosinopenia 19 6 13.16 (3.64–26.66) 19 (10−29) 64.8 (5–208)
Controls 382 213 10.74 (2.56–29.01) 15 (4−33) 14.4 (5–304)
p-value 0.05 0.09 0.03* 0.02*
An eosinophil count is a widely available and inexpensive biomarker. Eosinopenia
appears to be associated with severity of infection in CF pulmonary exacerbations.
